Skip to main navigation
Skip to search
Skip to main content
Sort by
Neuroscience
Amyotrophic Lateral Sclerosis
100%
Multiple Sclerosis
88%
Parkinson's Disease
76%
Cognitive Disorders
49%
Alzheimer's Disease
48%
Stem Cell
46%
Cerebral Hemorrhage
41%
Neurodegenerative Disorder
40%
Stereotypic Movement Disorder
40%
Systematic Review
38%
Cerebrovascular Accident
36%
Oligodendrocyte
34%
Nervous System Disorder
34%
Mild Cognitive Impairment
27%
Neurodegeneration
27%
Meta-Analysis
24%
Motor Neuron Disease
24%
Quality of Life
19%
Secondary Progressive Multiple Sclerosis
17%
Remyelinization
17%
Cerebrovascular Disease
16%
Myelinogenesis
16%
Central Nervous System
15%
Randomized Controlled Trial
15%
Frontotemporal Dementia
14%
Neuroprotective Agent
14%
Magnetic Resonance Imaging
14%
Executive Function
13%
Magnetic Resonance Imaging
13%
Myelin
13%
Relapsing Remitting Multiple Sclerosis
12%
Functional Neurological Disorder
11%
Antithrombotic
11%
In Vivo
11%
Cognitive Function
11%
Neural Stem Cell
10%
Comorbidity
10%
Placebo
10%
In Vitro
10%
Axon
10%
Dissociative
10%
Risk Factor
10%
Astrocyte
9%
Non-Motor Symptoms
9%
Brain Disease
9%
Neuropsychological Assessment
9%
Glia
8%
Gray Matter
8%
Hematoma
8%
Brainstem
8%
Brain Ischemia
8%
Behavior (Neuroscience)
8%
Behavior Change
8%
Nerve Fiber Degeneration
7%
Neuroscience
7%
Interferon
7%
Memory Disorder
7%
Riluzole
7%
Synapse
6%
Microglia
6%
Expanded Disability Status Scale
6%
Executive Dysfunction
6%
Cognitive Change
6%
Messenger RNA
6%
Mitochondrial Function
6%
Embryonic Stem Cell
6%
Tau Protein
6%
Major Depressive Disorder
6%
Fluoxetine
6%
Amiloride
5%
Mitochondrion
5%
Progenitor Cell
5%
Hypothermia
5%
Neuropsychiatric Symptom
5%
Glutamic Acid
5%
Progressive Supranuclear Palsy
5%
Clinical Assessment
5%
Mitochondrial DNA
5%
Longitudinal Study
5%
Vitamin K Antagonist
5%
Human Brain
5%
Computed Tomography
5%
Neuropsychological Test
5%
Biological Marker
5%
NMDA Receptor
5%
Diagnosis of Multiple Sclerosis
5%
Transcranial Magnetic Stimulation
5%
Dementia with Lewy Bodies
5%
Systemic Lupus Erythematosus
5%
Subarachnoid Hemorrhage
5%
Corticobasal Degeneration
5%
Axonal Degeneration
5%
Axoplasmic Transport
5%
Medicine and Dentistry
Cerebral Hemorrhage
76%
Multiple Sclerosis
71%
Apoplexy
55%
Systematic Review
55%
Diseases
49%
Randomized Controlled Trial
37%
Alzheimer's Disease
36%
Motor Neuron Disease
32%
Amyotrophic Lateral Sclerosis
32%
Meta-Analysis
31%
Stereotypic Movement Disorder
30%
Magnetic Resonance Imaging
26%
Placebo
24%
Neurologic Disease
23%
Parkinson's Disease
22%
Clinical Trial
21%
Oligodendrocyte
21%
Degenerative Disease
21%
Neurology
21%
Quality of Life
18%
Remyelination
17%
Biological Marker
17%
Antithrombotic
15%
Primary Outcome
15%
Cavernous Hemangioma
15%
Neuroprotective Agent
15%
Functional Neurological Disorder
13%
Cohort Effect
12%
Epileptic Seizure
12%
Neurodegeneration
12%
Observational Study
11%
Cohort Analysis
11%
Cognitive Defect
11%
Disease
11%
Arm
11%
Myelination
10%
UK Biobank
10%
Bilingualism
10%
Optical Coherence Tomography
9%
Central Nervous System
9%
Disease Exacerbation
9%
Functional Disorder
9%
Myelin
8%
Nervous System Disorder
8%
Induced Pluripotent Stem Cell
8%
Physiotherapy
8%
Interferon Type I
8%
Demyelination
8%
Adverse Event
7%
White Matter Lesion
7%
Cerebrovascular Disease
7%
Conservative Treatment
7%
Cerebral Arteriovenous Malformation
7%
Comorbidity
7%
Prevalence
7%
Sensitivity and Specificity
6%
Odds Ratio
6%
Cognitive Behavioral Therapy
6%
Vascular Amyloidosis
6%
Functional Assessment
6%
Caregiver Burden
6%
Primary Health Care
6%
Precursor
6%
Oligodendrocyte Precursor Cell
5%
Primary Progressive Aphasia
5%
Retinal Nerve Fiber Layer
5%
Weakness
5%
Age Related Macular Degeneration
5%
Antiplatelet
5%
Clinical Assessment
5%
Secondary Prevention
5%
Disease Course
5%
Stem Cell
5%
Vascular Anomaly
5%
Fluoxetine
5%
Amiloride
5%
Riluzole
5%
Neurodegenerative Disorder
5%
Major Depressive Episode
5%
Health Care Cost
5%
Functional Disease
5%
Cerebral Atrophy
5%
Ganglioglioma
5%
Patient Health Questionnaire 9
5%
Fluorine-18
5%
Limb Pain
5%
Neural Precursor Cells
5%
Hematoma
5%
Astrocyte
5%
Thrombocyte Transfusion
5%
Tranexamic Acid
5%
Memory Assessment
5%
Motor Performance
5%
Arteriovenous Malformation
5%
Single-Photon Emission Computed Tomography
5%
Simvastatin
5%
Expanded Disability Status Scale
5%
Hazard Ratio
5%
Oral
5%
Pharmacology, Toxicology and Pharmaceutical Science
Brain Hemorrhage
38%
Alzheimer's Disease
34%
Diseases
33%
Multiple Sclerosis
30%
Parkinson's Disease
29%
Placebo
25%
Amyotrophic Lateral Sclerosis
23%
Cerebrovascular Accident
18%
Randomized Controlled Trial
15%
Clinical Trial
14%
Degenerative Disease
13%
Neuroprotective Agent
12%
Neurologic Disease
11%
Motor Neuron Disease
9%
Anticoagulant Agent
9%
Riluzole
8%
Biological Marker
8%
Amiloride
8%
Fluoxetine
8%
Prevalence
7%
Adverse Event
7%
Frontotemporal Dementia
6%
Repurposing
6%
Mild Cognitive Impairment
5%
Brain Ischemia
5%
Disease Exacerbation
5%
Tolerability
5%
Migraine
5%
Subarachnoid Hemorrhage
5%
Congenital Blood Vessel Malformation
5%
Hematoma
5%
Cholinergic Receptor Blocking Agent
5%
Motor Dysfunction
5%